SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (54)11/12/2002 9:28:26 PM
From: Miljenko Zuanic  Respond to of 411
 
Thanks.

I am very curious to read (one day) what is included in NDA. They have open label extension data, but never made available.

3146 is interesting one, with lucrative deal for CVTX.

Miljenko



To: mopgcw who wrote (54)11/12/2002 9:57:58 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 411
 
Thanks very much! Just a note..... PSVT is not a subset for the trial, but a subset of arythmias. The phase III trial was PSVT only.

Haven't listened yet. No mention of the Biogen CHF collaboration? I'm beginning to fear that there's some mechanistic issue with A1R antagonists.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News